| First Author | Du J | Year | 2021 |
| Journal | Front Pharmacol | Volume | 12 |
| Pages | 825425 | PubMed ID | 35095535 |
| Mgi Jnum | J:319739 | Mgi Id | MGI:6864937 |
| Doi | 10.3389/fphar.2021.825425 | Citation | Du J, et al. (2021) The Effects of Combined Therapy With Metformin and Hydroxypropyl-beta-Cyclodextrin in a Mouse Model of Niemann-Pick Disease Type C1. Front Pharmacol 12:825425 |
| abstractText | Niemann-Pick disease type C1 (NPC1) is a neurodegenerative disorder characterized by lysosomal storage of free cholesterol. 2-Hydroxypropyl-beta-cyclodextrin (HPbetaCD) is a cyclic oligosaccharide derivative that is being developed to treat NPC1. Recently, metformin was reported to be beneficial in various neurodegenerative diseases, such as Alzheimer's and Huntington's diseases. In this study, we examined the effects of combined treatment with HPbetaCD and metformin on Npc1 (-/-) mice. Unfortunately, body weight and survival rates showed that cotreatment with metformin did not extend survival time and increase the body weight of HPbetaCD-treated Npc1 (-/-) mice. However, cotreatment with metformin reduced inflammatory response and inhibited the proinflammatory cytokine release in the brain, liver and spleen of HPbetaCD-treated Npc1 (-/-) mice. Furthermore, metformin did not reduce the free cholesterol levels in Npc1 (-/-) brain tissue or fibroblasts. In conclusion, our results demonstrate that metformin does not show beneficial effects on body weight or survival time but reduced the inflammatory response in a mouse model of NPC1 when combined with HPbetaCD. |
